UK respiratory drug market was $11.1 billion in 2018 and is anticipated to grow at a substantial rate of 7.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in Europe. Respiratory drugs are used for treatment of patient from asthma attacks and other respiratory ailments. As the prevalence of asthma and other diseases increases across UK, the demand of respiratory drugs is also expected to increase for treatment purposes. As per International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises of England, Scotland, Wales and Northern Ireland. Total population of the country in 2017 was 65 million, out of which about 18% are of geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by government and people can be forecast in the near future.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/uk-respiratory-drug-market
The UK respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the nation. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/uk-respiratory-drug-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drug to cater to a wide range of customers within and outside the region. The major players of the UK respiratory drug market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Market Segmentation
UK Respiratory Drug Market by Route of Administration
- Oral
- Injectable
- Inhalable
UK Respiratory Drug Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
UK Respiratory Drug Market by End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- Air Liquide S.A.
- Aradigm Corp.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Merck & Co.
- Novartis AG
- Omron Healthcare Inc.
- Pfizer Inc.
- Pulmatrix Inc.
- ResMed Corp.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceuticals Industries Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
